Spark's Gene Therapy Luxturna Sails Through US FDA Panel
Executive Summary
Improvements seen in multi-luminance mobility testing in the voretigene Phase III trial were clinically meaningful, panelists said, endorsing the novel endpoint for the vision loss treatment. They also were persuaded by first-hand accounts from patients.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
